Shield Therapeutics plc (STX.L)

GBp 2.75

(0.0%)

Market Cap (In GBp)

21.5 Million

Revenue (In GBp)

13.08 Million

Net Income (In GBp)

-33.29 Million

Avg. Volume

5.08 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.063-7.797
PE
-
EPS
-
Beta Value
1.515
ISIN
GB00BYV81293
CUSIP
G8123P102
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Anders Lundstrom
Employee Count
-
Website
https://www.shieldtherapeutics.com
Ipo Date
2016-02-26
Details
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.